not only inhibiting these processes [2] , but sometimes activating them [3] .
Formerly the clinical observations of Stenkvist and collaborators have shown the beneficial effects of digitalis treatments in women with breast cancer: very few patients treated with CS for chronic heart problems died of cancer [4, 5] . For this reason various laboratories have explored the role of ouabain and similar compounds as antiproliferative agents. For example CS induced apoptosis in human prostate cancer cell lines [6] . Other investigators found that ouabain and digoxin selectively induced apoptosis in a human acute T-cell lymphoblastic leukemia cell line [2] . In the estrogen dependent/independent breast cancer cell lines, CS similarly exerted antiproliferative effects, suggesting their potential use as anticancer agents [7] .
(cod. 9271), anti-P70S6K (cod. 2708), anti-phospho-P70S6K (Thr 389 ) (cod. 9234) all from Cell Signaling Technology and mouse monoclonal anti-β-Actin antibody (cod. A5441) from Sigma-Aldrich. Secondary antibodies were: horseradish peroxidase-labeled goat anti-mouse or anti-rabbit (Jackson ImmunoResearch laboratories Inc., West Grove, PA, USA).
Patients
Adrenocortical tumor tissues were obtained from 1 patient with ACC and 4 patients with aldosterone-producing adenomas (APA). The etiology of each adrenocortical mass, clinical diagnose and staging were established as described [9] . All clinical data are summarized in Table 1 . All patients gave written informed consent to the collection and use of adrenal tissue for research purposes, and the study was approved by the local ethics committee (conforming to the Declaration of Helsinki, revised in Tokyo, 2004) .
Cell cultures
H295R and SW13 adrenocortical tumor cell lines were obtained from the American Type Culture Collection (ATCC, Rockwille, MD). H295R cells were established from a female patient diagnosed with an adrenocortical carcinoma. This strain secretes mineralcorticoids, glucocorticoids and adrenal androgens. SW13 cells were derived from a small cell carcinoma in the adrenal cortex of a 55-year-old female, probably a metastasis to the adrenal cortex. This strain produces no steroid [11] . Five primary cell cultures were also studied, 1 ACC and 4 APA. All experiment involving cell manipulation were conducted incubating cell lines with 0.1% FBS as previously described [12] .
MTT assay
Cells were plated in 96-well plates at a density of 5x10 3 cells/well in supplemented medium with or with-Everolimus (RAD001) is a derivative of rapamycin acting on the mammalian target of rapamycin (mTOR), a key component of PI3K/Akt pathway, frequently activated in human cancers. It is a well-known compound currently used for the treatment of renal cell cancer and other tumors [8] . Recently we described its antiproliferative effect in adrenocortical tumor models in association with sorafenib [9] .
Adrenocortical tumors can be benign or malignant. Benign tumors are frequent in the general population, being commonly discovered incidentally (incidentaloma) and may be functional or nonfunctional. Malignant adrenocortical carcinoma (ACC) has a poor prognosis with an estimated survival rate of 35% at 5 years, and to date pharmacologic therapy is principally based on the adrenotoxic drug, mitotane (o,p′-DDD), despite its low response rate and significant toxicity [10] . As this regimen is insufficient, it is necessary to develop new treatment modalities.
To determine whether ouabain alone, or in combination with everolimus, exerts antineoplastic activity, we explored its effects on cell viability, cell proliferation, cell morphology, cell cycle and apoptosis in SW13 and H295R cells (the 2 most frequently used adrenocortical cell models), and in primary adrenocortical tumor cells.
Materials and Methods

Materials
Ouabain, everolimus, fetal bovine serum (FBS), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), trichloracetic acid (TCA) and propidium iodide were purchased from Sigma Aldrich (Sigma Aldrich Corporation, St. Louis, MO, USA). DMEM-F12, 0.05% trypsin-EDTA, insulin, transferrin, selenium and antibiotics were from Invitrogen (Invitrogen S.R.L. Milano, Italy). Primary antibodies were: anti-Akt (cod. 9272), anti-phospho-Akt (Ser 473 ) in ice-cold PBS and fixed in 70% ice-cold ethanol, followed by an overnight incubation at -20°C. After washing, cells were stained with PI solution (50µg/mL PI, 10µg/mL RNaseA) and incubated for 1h at 37°C in the dark. Cell cycle analysis was performed in triplicates and data were assessed by CXP analysis software.
Homogeneous caspases assay
H295R and SW13 cells were plated into 96-well plates at a density of 2x10 4 cells/well and were treated with ouabain (1, 10, 100, 1000nM) for 24h and 72h. Total caspase activity was evaluated with a Homogeneous Caspases Assay Kit (Roche Diagnostics GmbH, Mannheim, Germany) following the manufacturer's instructions. In brief, substrate solution was added to cell lysate for 2h at 37°C and relative fluorescence was measured with excitation and emission filters (λex=499nm and λem=520nm). Data were corrected by subtracting the blank absorbance and concentrations estimated against a calibration curve obtained with R110 standard solutions. Each experiment was performed in triplicate and repeated twice.
Apoptosis flow cytometry analysis
Apoptosis was determined by Annexin V-FITC kit (BD Biosciences, San Diego, CA, USA). In brief, H295R and SW13 cells were plated into 25 cm 2 flasks at a density of 1x10 6 cells/well for two days, then maintained overnight at 0.1% FBS. The day after the cells were treated with ouabain alone (1, 10, 100, 1000nM) for 24 and 72 h or in combination with everolimus 5µM, trypsinized and harvested by centrifugation. Cells were then stained with Annexin V-FITC and propidium iodide according to the manufacturer's instruction.
Flow cytometry analysis was also performed on 2 primary adrenocortical tumor cells: APA-1 and ACC. The concentrations of ouabain used were 1, 10, 100, 1000 nM and the time of treatment was 24h. Analysis was performed in duplicate.
Western blot analysis
Cells were treated with different concentrations of ouabain 1, 10, 100 nM at 24h for SW13 cells and 1, 10, 100, 1000nM at 24h for H295R cells as previously described [9] . In addition everolimus (5 µM) was used in combination with ouabain. Briefly proteins were extracted with lysis buffer containing a protease inhibitor cocktail (Sigma-Aldrich) for 1h at 4°C, loaded onto SDS/PAGE, electroblotted onto nitrocellulose mem-out ouabain. Drug incubation was carried out at different concentrations 1, 10, 50, 100, 200, 500, 1000nM (and 5000, 10000nM, data not shown). Everolimus was used alone or in combination with ouabain at 5 µM. Methods and percentage of cell survival were as previously described [12] . Each analysis was performed on 4 replicates and repeated in 2 independent experiments.
MTT assay was also performed on 5 primary adrenocortical tumor cells, 1 ACC and 4 APA. The concentrations of ouabain used were 1, 10, 100, 1000 nM for 24h or 72h (and 120h for APA-1 primary tumor cell culture).
[ 3 H] thymidine assay
H295R and SW13 cells were seeded in 24-well plates at a density of 2x10 5 cells/well and incubated with varying concentrations of ouabain (1, 10, 100, 1000nM) for 24h and 72h. Six hours before ending the experiment, 1 µCi/well of [ 3 H] thymidine (PerkinElmer, Monza, Italy) was added to the medium. Then cells were washed once with 10% TCA and twice with 5% TCA. Subsequently cells were lysed in 1 mL of 0.5 M NaOH. Scintillation liquid (Ultima Gold, PerkinElmer, Monza, Italy) was added and radioactivity incorporated into DNA measured in a scintillation counter (Wallac, PerkinElmer, Monza, Italy). The results are expressed as a percentage of control (100%). Each experiment was performed in quadruplicate and repeated 3 times.
Assessment of apoptosis and necrosis by Wright's staining
H295R and SW13 cells were cultured on coverslips for 48h, incubated overnight in 0.1% FBS, and then incubated with drug for 24h at different concentrations (1, 10, 100, 1000nM) for both cell lines. The cells were then washed in PBS, fixed in methanol for 5 min and Wright's stained for 5 min. Cell morphology was evaluated by light microscopy at x400 magnification. At least 600 cells were counted for every experiment in 4 different fields and each experiment was repeated twice. One primary tumor cell culture (APA-1) was evaluated with ouabain (10, 100, 1000nM) for 120h.
Cell cycle distribution analysis
H295R and SW13 cells were plated into 25 cm 2 flasks at a density of 1x10 6 cells/well and were treated with ouabain alone (1, 10, 100, 1000nM) for 24 and 72h or in combination with everolimus (5µM), trypsinized and harvested by centrifugation. Cells were resuspended ences were seen between 24h and 72h treatments in both cell lines ( Fig. 2 ).
Ouabain alters cell morphology in SW13, H295R and primary adrenocortical tumor cells
To evaluate cell morphology, Wright's staining method was used. As shown in Fig. 3 , apoptosis, determined by blebbing, cell shrinkage, nuclear fragmentation, condensation of chromatin and necrosis, was determined by cell disruption and membrane breakdown, both of which were clearly detected. Marked morphological changes were observed both for SW13 and H295R cells ( Fig. 3A-D) . In H295R, SW13 and in primary adrenocortical tumor cells (APA-1), necrotic processes were similarly predominant over apoptotic processes (data not shown).
Ouabain induces cell cycle deregulation in SW13 cells
To study the cell cycle distribution, PI assays were performed. In H295R cells, ouabain treatment alone or in combination produced no effect at 24h, but at 72h a slight G0/G1 phase increase after ouabain treatment alone (1000nM) or combination regimen (ouabain 1000nM + everolimus 5µM) was detected (data not shown). In SW13 cells, ouabain treatment promoted a G0/G1 phase increase both at 24h and 72h, with a concomitant S and G2/M phases reduction, particularly evident at 100 and 1000nM at 72h (Fig. 4A ). Combination treatment produced no change in G0/ G1 phase, a slight increment in S phase and a slight decrease in G2/M phase, especially evident when ouabain 1000nM + everolimus 5µM was used ( Fig. 4B ).
Ouabain affects caspase activity in SW13 and H295R cells
To assess the first steps of apoptotic process, the activation of a particular group of proteases, the caspases, was analyzed by a specific assay in both cell lines. The activity of caspases evaluated at 24h are not dissimilar to basal for both cell lines, despite a statistical difference ( Fig. 5A-B ). The effect of ouabain (10, 100 and 1000nM) on caspase activity proved to be more marked at 72h for both cell lines; in SW13 cells, caspase activity clearly increased at 100 and 1000nM ouabain at 72h (Fig. 5B ).
Ouabain does not induce apoptosis in SW13, H295R and in primary adrenocortical tumor cells
To discriminate between apoptosis and necro-branes, blocked for 1h with 5% nonfat dry milk and incubated overnight with different primary antibodies. After secondary antibody, immunoreactivity was detected with LiteAblot Extend Long Lasting Chemiluminescent Substrate (EuroClone). Films were scanned and band intensity quantified with ImageJ software 1.44p. Each experiment was performed in triplicate.
Statistical analysis
Statistical analysis were performed using GraphPad Prism 4 software (GraphPad Software, Inc., San Diego, CA) and Microsoft Excel software. Data comparisons were performed using the two-tailed Student's t test and Kruskal-Wallis analysis followed by Dunn's posthoc test. P<0.05 was considered statistically significant. Data are presented as mean ± standard error of the mean (SEM).
Results
Ouabain and everolimus affect cell viability in SW13, H295R and in primary adrenocortical tumor cells
To examine cell viability in SW13, H295R and primary adrenocortical tumor cells, MTT assay was performed. As shown in Fig. 1A-B , ouabain induced a concentration and time-dependent decrease in cell viability in SW13 cells with an IC 50 of 48±1nM at 24h, and of 6.6±1nM at 72h; at 72h an extrapolated IC 50 of 120±17nM was obtained for H295R cells. Combination strategy led to similar results to those with ouabain alone, but 72h cell viability was considerably more reduced at lower ouabain doses in H295R cells (ouabain 10/100nM + everolimus 5µM) ( Fig. 1C-D) .
The data in Fig. 1E -F point out that in primary adrenocortical tumor cells (ACC and APA-1) the effect of ouabain was more evident when cells were treated at 1000 nM at 72h. In the 3 other APA samples no similar result was found (data not shown).
Ouabain affects cell proliferation rate (DNA synthesis) of SW13 and H295R cells
To assess the proliferation rate of SW13 and H295R cells, sis, Annexin V-FITC/propidium iodide staining and flow cytometry were performed in both cell models and 2 primary adrenocortical tumor cells (1 ACC and APA-1). In SW13 cells, we observed a clear increase in necrotic processes at 1000nM after 24h (data not shown). At 72h we detected a very toxic effect of ouabain especially at 100 and 1000nM with high levels of necrosis ( Fig. 6A-B) , very similar to combination treatment ( Fig. 6C-D) . No appreciable effect was evident for apoptosis or necrosis in H295R cells at 24h and 72h (both with ouabain alone or combination treatment), and in ACC primary tumor cells, ouabain exerted a slight necrotic effect at 1000nM, with no effect evident in APA primary cells (data not shown).
Ouabain and everolimus suppress PI3k/Akt signaling pathways in SW13 cells
To evaluate the PI3k/Akt signaling pathway involved in apoptosis, survival and proliferation, Western blot analysis was done on both cell lines. No substantial change was observed for H295R cells, except for an absence of reactivity for phosphorylated p70S6k, both in ouabain ( Fig. 7A ) and combination treatments (Fig.  7C ). An ouabain concentration dependent effect was particularly evident at 1000nM drug treatment. The results were different for SW13 cells, which showed a decrease in Akt, p-Akt, p70S6k and p-p70S6k reactivity after ouabain administration (Fig. 7B) or after combination regimen (Fig. 7D) . Band quantification statistical analysis are in Supplemental Tables 1, 2 . to 1000nM. In combination strategy we used everolimus at 5µM, a concentration already tested in adrenocortical tumors [9] . The present study demonstrated that ouabain alone or in combination with everolimus induced a decrease in cell viability, as shown by MTT assay. The activity of ouabain was more pronounced in SW13 cells and seemed to be time and concentration dependent ( Fig.  1A-E) . In H295R cells the efficacy of ouabain seemed to be related to time of treatment, as only at 72h was it possible to reach the IC 50 (Fig. 1A) . The difference between the 2 cell lines might mainly reflect the longer doubling time of H295R than SW13, even if other cell-intrinsic causes (biochemical/cytological) are also involved; in fact H295R cells carry mutations in different genes, such as CTNNB1, TP53, etc. [15] .
These data are in line with previous findings, where cytotoxic effect of ouabain in a panel of cancer cell lines were seen at an IC 50 ranging from 50-100nM [16] ,
Discussion
To our knowledge, this is the first time that antiproliferative effects of ouabain have been investigated in an established adrenocortical cell line (H295R), in a cell line from a suspected adrenal metastasis (SW13) and in 5 primary adrenocortical tumor cells. We used H295R cell line as an effective model of adrenocortical tumor: this line requires a longer population doubling time >72-96h and produced adrenal steroids, whereas SW13 cells show a rapid duplication time of 36-48h [11] . In the literature no data are available about the therapeutic range of ouabain in serum, even though Clark and collaborators found a range of 0.6-3.2nM for digoxin, which is a CS similar to ouabain in structure and properties [13] .
Based on this information and on the fact that to block Na + /K + -ATPase lethal concentrations of ouabain (>10 6 M) are needed, we sought to treat cells from 1nM intracellular biochemical events during apoptosis [21] . It is noteworthy that the usual subdivision of necrosis versus apoptosis is a simplification of a more intricate picture. In fact cell death represents contributions by different cell processes, in which apoptosis and necrosis are overlapping phenomena; such overlapping cell death pathways are common behavior rather than an anomaly [22] . We found activation of caspases (indicative of apoptosis), especially at 72h in SW13 cells, but a major increase in necrosis was found, clearly revealed by cell morphological evaluation ( Fig. 3 ) and FACS analysis with Annexin V-FITC and propidium iodide (Fig. 6) .
These results are not in contrast, because: a) the activation of caspases is an early event in cell apoptosis, but after ouabain triggers apoptosis, cells may not be able to complete the process and subsequently undergo death via necrosis [23] ; b) some caspases (1 and 8) have been observed as driving events toward necrosis and consequently ouabain may activate this process via caspase [23] ; c) as previously mentioned, the two different processes may be simultaneously present in a dying cell; d) the translocation of phosphatidylserine to the outer leaflet of cell membrane (evaluated by FACS analysis) may be uncoupled from caspase activation and consequently the 2 processes may occur at different times [24] . Moreover a combination regimen seemed not differently affect cell fate, since the results are similar to those obtained with the ouabain alone. Further studies are needed to discriminate between different modalities of cell death in adrenocortical cell lines. We analyzed the PI3k/Akt signaling pathways. Constitutive activation of this pathway is found in many malignancies and also in H295R and SW13 cells, as demonstrated in our previous work [9] . In H295R cells, ouabain induced a reduction in p-p70S6k. On the one hand this effect may be associated with decreased proliferation and survival, as underlined by [ 3 H] thymidine assay, FACS analysis and homogeneous caspase assay. On the other, it may suggest that a specific biomolecular mechanism is modulated by ouabain between Akt and p70S6k, although more research is needed to confirm this hypothesis. As expected, everolimus inhibited p-p70S6k both alone or in combination with ouabain. In SW13 cells, we observed a more general effect, probably indicating that ouabain exerts its consequences on the entire pathway. Blocking PI3k/Akt signaling pathways by ouabain may be therapeutically attractive, as it was for everolimus, but this speculation needs to be adequately corroborated. [17] . It is noteworthy that combination therapy (ouabain 10-100nM + everolimus5µM) proved to be more successful in term of cell viability reduction in H295R cells at 72h compared with treatment alone (Fig. 1C) .
Primary adrenocortical tumor cells showed no change in cell viability at 24h, but at 120h for APA-1 sample, and in some measure at 72h for another APA sample, we noted a sharp decline of cell viability (70-80%) at 1000nM, probably indicating that ouabain has enough time to act on growing cells (Fig. 1F ) and underlining the importance of protracted treatment.
The [ 3 H] thymidine incorporation assay confirmed that ouabain interferes with cell proliferation, thus causing growth arrest (Fig. 2) . A stochastic fall is clearly visible between 10nM and 100nM ouabain, suggesting that drug treatments are not faithfully following a sigmoidal curve. Ouabain treatment at 100nM and 1000nM may imply an interference with DNA synthesis, but not with cell viability, as at 100nM (especially in H295R cell) about 50% of cells were still viable by MTT test.
Taken together, all the above results suggest that ouabain may exert antiproliferative effects on tumor cell lines, especially on SW13 cells, even if not at lower concentrations. One previous study reported that ouabain at very high concentration (1 and 10 µM) showed antiproliferative results on 3 different prostate cancer cell lines [14] . A second study described the effects of ouabain (from 0.01 to 100µM) on viability on a small panel of cancer cell lines with essentially the same results [18] . Furthermore combination strategy seemed to be more successful in H295R cells, at least in cell viability and proliferation assay.
Examination of cells by microscopy allows accurate distinction between necrosis and apoptosis [19] . Wright's staining results clearly indicated that necrotic processes predominated over apoptosis (Fig. 3) . The DNA cell cycle distribution was altered by ouabain only in SW13 cells, while combination treatment revealed no substantial change in both cell lines. In agreement with our data on ouabain, a previous study analyzed 2 different human hepatocellular cell lines for cell cycle distribution at 24h, after treatment with ouabain at 100 and 500 nM [20] .
To discriminate between the two different cellular fates, apoptosis and necrosis, and to confirm microscopy data, we performed the homogeneous caspase assay and FACS analysis by Annexin V and propidium iodide. The first method analyzes the activation of different caspases: 2, 3, 6, 7, 8, 9 and 10, one of the initial Our study has shown for the first time antiproliferative effects of ouabain on SW13 and H295R cell models and on primary adrenocortical tumor cells. The results obtained are promising, but more data are needed to fully explore the role of ouabain as a potential anticancer drug.
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